J

Johnson & Johnson

Makes prescription drugs and medical devices

Transcend Deployment Logistics Manager

Full-TimePosted on 10/20/2026Deadline 10/28/26
$112.2k - $162.2k+ Discretionary performance bonus
Senior
Bachelor's, Master's
Toronto, ON, Canada
Hybrid
Project & Program ManagementProgram Management

About the job

Requirements
  • A bachelor's degree in Supply Chain, Engineering, Business, Information Systems, Logistics, or a related field is required.
  • A minimum of 6 years of experience in Supply Chain, Logistics, ERP Deployment, Operations, or Program Management is required.
  • Experience implementing enterprise systems such as SAP ECC, SAP S/4HANA, Oracle, or equivalent ERP platforms is required.
  • Experience leading cross-functional projects in a complex, global environment is required.
  • Strong understanding of logistics, warehousing, transportation, and inventory management processes is required.
  • Experience working with third-party logistics providers is required.
  • Strong enterprise mindset and strategic thinking are required.
  • Ability to influence across all levels of the organization is required.
  • Strong communication and stakeholder management skills are required.
  • Data-driven decision making is required.
  • A continuous improvement mindset is required.
  • Ability to navigate ambiguity and drive results is required.
  • Strong collaboration and team leadership capabilities are required.
  • Passion for transforming business processes through technology is required.
  • Ability to translate complex technical concepts into business outcomes is required.
  • Proven success delivering results in matrixed environments is required.
  • Commitment to the company's Credo values and a patient-first mindset is required.
Responsibilities
  • Lead logistics deployment activities for program releases and site implementations.
  • Partner with global process owners and deployment teams to execute best-practice deployment strategies and timelines.
  • Drive logistics workstream readiness assessments and risk mitigation plans.
  • Ensure alignment between business requirements and standardized global solutions.
  • Support inventory management, warehouse management operations, shop floor inventory management, transportation management, distribution and fulfillment, third-party logistics integration (including off-site storage sites and vendor-managed inventory), batch traceability and serialization, and goods receipt, internal goods movements, and goods issue processes.
  • Facilitate fit-gap discussions and deployment decisions with business stakeholders.
  • Coordinate business simulation testing, user acceptance testing, training, and cutover activities.
  • Ensure business users are prepared to adopt new processes and technologies.
  • Develop deployment communications and executive status reporting.
  • Manage stakeholder expectations and drive issue resolution.
  • Partner with Manufacturing, Planning, Procurement, Quality, Finance, and IT organizations.
  • Collaborate with external logistics providers and integration partners.
  • Support master data readiness and data governance activities.
  • Identify process improvement opportunities that enhance service, efficiency, and compliance.
  • Track deployment risks, issues, dependencies, and mitigation plans.
  • Present deployment readiness updates to leadership teams and governance forums.
  • Monitor deployment KPIs and stabilization activities after go-live.
  • Ensure adherence to compliance, quality, and validation requirements.
Desired Qualifications
  • A master's degree is preferred.
  • Experience supporting global ERP transformation programs is preferred.
  • Knowledge of healthcare, pharmaceutical, medical device, or regulated industries is preferred.
  • Experience with deployment methodologies, cutover planning, and change management is preferred.
  • Familiarity with master data management and systems integration is preferred.
  • Certification in Project Management (PMP), Agile, Lean, or Six Sigma is preferred.
  • Knowledge of SAP S/4 transactional processes and tables is preferred.
  • Familiarity with IM/GL and data migration processes is preferred.
  • Skills listed as preferred include business process design, compliance management, cost management, data savvy, demand planning, developing others, distribution resource planning, financial competence, inclusive leadership, inventory management, inventory optimization, inventory turnover, leadership, logistics optimization, manufacturing flow management, motivating people, organizing, resource allocation, supply planning, and team management.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

6 month growth

6%

1 year growth

-2%

2 year growth

-2%
Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 23rd, 2026
Smith & Nephew's $22B talks to buy J&J's orthopaedics unit collapse over who would lead

Smith & Nephew's merger talks with Johnson & Johnson (J&J) over its orthopaedics unit collapsed over who would lead the combined company, the Financial Times reported. The sides had reportedly agreed on the main financial terms and the deal structure. J&J wanted Namal Nawana, who runs its orthopaedics unit and formerly led Smith & Nephew, to lead the business. Smith & Nephew wanted current chief executive officer Deepak Nath to stay. Smith & Nephew's offer valued J&J's hip and knee unit at up to $22 billion, almost double its own market value. J&J shareholders would have owned 50.1% of the combined company. J&J is leaning toward spinning off the unit as DePuy Synthes, targeting mid-2027. Reuters reported the unit sought around $20 billion and drew private equity interest. Both companies declined to comment.

Yahoo Finance
Oct 23rd, 2026
ETFs sell $54.1M of Johnson & Johnson, extending two-day selling streak

ETFs sold a net $54.1 million of Johnson & Johnson (JNJ) shares on Wednesday, extending a two-day run of net selling. Twenty-five funds cut their holdings, 24 added shares, and 153 held steady. The Health Care Select Sector SPDR (XLV) led the selling, cutting 153,134 shares worth $39.5 million. The iShares Core S&P 500 ETF (IVV) sold $11.5 million, and the iShares MSCI USA Momentum Factor ETF (MTUM) sold $5.4 million. Tuesday saw net selling of $20.0 million, after net buying of $38.1 million on Monday and $84.4 million on October 16. JNJ has a market cap of $644.9 billion and has returned 31.39% year to date.

Yahoo Finance
Oct 22nd, 2026
JNJ rated buy with $289 target as pharma growth of 8% outpaces MedTech's 2.5%

Johnson & Johnson (JNJ) earns a "buy" rating from 24/7 Wall St., with a 12-month price target of $288.66. That implies 11.48% upside from the $258.93 close on October 20. Growth is coming from pharma. Innovative Medicine sales rose 7.9% last quarter, while MedTech grew 2.5%. The analyst says the stock hinges on whether devices can close that gap. Third-quarter sales reached $25.4 billion. Adjusted earnings per share (EPS) were $2.59, but GAAP EPS fell to $0.09 after about $7 billion of charges, mostly tied to a proposed talc settlement and two deals. Management cut adjusted EPS guidance to $11.05 to $11.15. The bull case is $302.93, or 17% upside. Tremfya grew 68%, and management expects it to become a $10 billion-plus franchise.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.